Evaluating kidney damage through blood tests in prostate surgery patients
The Assessment of Kidney Damage Using NGAL Measurements in Patients Undergoing Robotic Radical Prostatectomy
This study is testing if a new blood test can better detect early kidney damage in patients having robotic prostate surgery compared to traditional kidney function tests.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 55 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Male |
| Sponsor | Ankara City Hospital Bilkent Academic / other |
| Locations | 1 site (Ankara, Çankaya) |
| Trial ID | NCT06274125 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine if measuring Neutrophil Gelatinase-Associated Lipocalin (NGAL) in blood is more effective than traditional kidney function tests (sCr and BUN) for early diagnosis of kidney damage in patients undergoing robotic urological surgery. The study will include 55 patients aged 18-80 with ASA scores of 1-3, who will be monitored preoperatively and postoperatively for various health parameters. Data collected will include demographic information, comorbidities, and standard biochemical profiles to assess the relationship between acute kidney injury (AKI) development and these monitored parameters.
Who should consider this trial
Good fit: Ideal candidates are patients aged 18-80 with ASA scores of 1-3 scheduled for robotic-assisted laparoscopic radical prostatectomy.
Not a fit: Patients with pre-existing renal disease or those classified as ASA-3 or higher will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection of kidney damage in patients undergoing robotic surgery, potentially enhancing patient outcomes.
How similar studies have performed: Other studies have shown promising results using NGAL as a biomarker for kidney injury, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * A total of 55 patients, with ASA scores 1-2-3, aged between 18 and 80 years, will be included in the study conducted at the Robotic Surgery operating room of Ankara City Hospital, Ministry of Health, Turkey. Exclusion Criteria: -1. Individuals who do not have the ability to read, understand, or sign the consent form. 2. Individuals with diagnosed renal disease. 3. Patients who do not wish to participate in the study. 4. Patients classified as ASA-3 or higher.
Where this trial is running
Ankara, Çankaya
- Ankara Bilkent City Hospital — Ankara, Çankaya, Turkey (Recruiting)
Study contacts
- Study coordinator: Aslı Demircioğlu
- Email: asli.demircioglu92@gmail.com
- Phone: 5383118012
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.